KM Research Hub
← 返回论文库
待处理 入排:待复核 图源:待检查 入排置信度 0.45

Interaction Between SNP Genotype and Efficacy of Anastrozole and Exemestane in Early-Stage Breast Cancer.

Junmei Cairns, Krishna R Kalari, James N Ingle, Lois E Shepherd, Matthew J Ellis, Paul E Goss, Poulami Barman, Erin E Carlson, Barbara Goodnature, Matthew P Goetz, Richard M Weinshilboum, Huanyao Gao, Liewei Wang

Clin Pharmacol Ther 110(4) 1038-1049

PMID34048027
PMCIDPMC8449801
DOI10.1002/cpt.2311
发表日期2021-05-28
入排依据:While the record describes an oncology, human, randomized, Phase III drug trial, the abstract does not report a primary or key secondary time-to-event efficacy endpoint (e.g., OS, PFS, DFS) with Kaplan-Meier or HR. It is a pharmacogenomic subgroup analysis of SNP-treatment interactions, not a primary efficacy result report. Therefore, it does not meet the criteria for inclusion in a Kaplan-Meier digitization cohort.
摘要

摘要

Aromatase inhibitors (AIs) are the treatment of choice for hormone receptor-positive early breast cancer in postmenopausal women. None of the third-generation AIs are superior to the others in terms of efficacy. We attempted to identify genetic factors that could differentiate between the effectiveness of adjuvant anastrozole and exemestane by examining single-nucleotide polymorphism (SNP)-treatment interaction in 4,465 patients. A group of SNPs were found to be differentially associated between anastrozole and exemestane regarding outcomes. However, they showed no association with outcome in the combined analysis. We followed up common SNPs near LY75 and GPR160 that could differentiate anastrozole from exemestane efficacy. LY75 and GPR160 participate in epithelial-to-mesenchymal transition and growth pathways, in both cases with SNP-dependent variation in regulation. Collectively, these studies identified SNPs that differentiate the efficacy of anastrozole and exemestane and they suggest additional genetic biomarkers for possible use in selecting an AI for a given patient.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。